longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Regeneron Pharma

REGN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 18.42, within the reasonable range, cheaper than 43.42% of the time in the past 3 years, and the industry ranks 37/601, the industry Median -2.34.

18.42xP/E
$774.61Stock price
$42.04Earnings per share
18.42xP/E
Stock price$774.61Earnings per share$42.04

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
17.61x
Typical range
14.61x–25.37x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
23.27x10.72%$203.47B
VRTXUSVertex Pharma
29.53x36.49%$130.09B
REGNUSRegeneron Pharma
18.42x4.10%$79.75B
INCYUSIncyte
15.68x65.04%$25.29B
UTHRUSUnited Therap
16.31x6.53%$21.38B
GMABUSGenmab A/S
26.84x24.93%$21.15B
ASNDUSAscendis Pharmac
18.92x479.53%$16.29B
NBIXUSNeurocrine Biosciences
21.54x50.66%$15.20B
EXELUSExelixis
16.35x16.46%$14.07B
HALOUSHalozyme Therap
29.76x181.51%$12.31B
TGTXUSTG Therap
19.36x65.83%$8.55B
VCYTUSVeracyte
27.03x35.02%$3.10B
CDNAUSCaredex
24.96x629.58%$2.77B
MGTXUSMeiraGTx
15.52x122.03%$1.23B
PBYIUSPuma BioTech
18.14x37.70%$484.71M
KMDAUSKamada
21.24x39.29%$472.65M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.